Clinical Trials List
2023-03-01 - 2027-04-30
Phase III
Recruiting9
Terminated1
ICD-10I25.10
Atherosclerotic heart disease of native coronary artery without angina pectoris
ICD-9429.2
Cardiovascular disease, unspecified
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
IQVIA
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 傅家保 Division of Endocrinology
- 李宇璇 Division of Endocrinology
- WEI-WEN LIN Division of Endocrinology
- 蔡易婷 Division of Endocrinology
- Yu-Cheng Hsieh Division of Endocrinology
- I-TE LEE Division of Endocrinology
- 沈宜靜 Division of Endocrinology
- 鄭由承 Division of Endocrinology
- 鄭諭聰 Division of Cardiovascular Diseases
- 林時逸 Division of Geriatrics
- 李佳霖 醫學研究部
- 張之昀 Division of Endocrinology
- 王奇彥 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 洪大川 Division of Cardiovascular Diseases
- 陳俊延 Division of Cardiovascular Diseases
- 林書毅 Division of Cardiovascular Diseases
- 洪崇烈 Division of Cardiovascular Diseases
- 劉俊傑 Division of Cardiovascular Diseases
- 程崇偉 Division of Cardiovascular Diseases
- 陳律安 Division of Cardiovascular Diseases
- 郭任遠 Division of Cardiovascular Diseases
- 李應湘 Division of Cardiovascular Diseases
- 廖峰慶 Division of Cardiovascular Diseases
- 林肇鋒 Division of Cardiovascular Diseases
- 蘇正煌 Division of Cardiovascular Diseases
- 李俊偉 Division of Cardiovascular Diseases
- 簡禎彥 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張懷仁 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳韋璁 Division of Cardiovascular Diseases
- Po-Chao Hsu Division of Cardiovascular Diseases
- Ye-Hsu Lu Division of Cardiovascular Diseases
- Chun-Yuan Chu Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張獻元 Division of General Internal Medicine
- 黃睦翔 Division of General Internal Medicine
- Po-Tseng Lee Division of General Internal Medicine
- Ju-Yi Chen Division of General Internal Medicine
- 柯呈諭 Division of General Internal Medicine
- 李文煌 Division of General Internal Medicine
- Po-Sheng Chen Division of General Internal Medicine
- 黃鼎鈞 Division of General Internal Medicine
- Cheng-Han Lee Division of General Internal Medicine
- 陳柏偉 Division of General Internal Medicine
- Shih-Hung Chan Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林柏志 Division of General Internal Medicine
- 陳盈憲 Division of General Internal Medicine
- YEN-HUNG LIN Division of General Internal Medicine
- Juey-Jen Hwang Division of General Internal Medicine
- JEN-KUANG LEE Division of General Internal Medicine
- CHO-KAI WU Division of General Internal Medicine
- MAO-HSIN LIN Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
9 Completed
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Age 18 to ≤ 85 years
Lp(a)≥ 200 nmol/L during screening
History of ASCVD as evidenced by history of either:
Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.
Exclusion Criteria
Severe renal dysfunction
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN), or total bilirubin (TBL) > 2 x ULN during screening
History of hemorrhagic stroke
History of major bleeding disorder
Planned cardiac surgery or arterial revascularization
Severe heart failure
Current, recent, or planned lipoprotein apheresis
Previously received ribonucleic acid therapy specifically targeting Lp(a)
The Estimated Number of Participants
-
Taiwan
75 participants
-
Global
6000 participants
